CORDIS
EU research results

CORDIS

English EN
Novel multifunctional cyclodextrin-based nanocarriers for drug encapsulation and delivery as a strategy to overcome current therapeutic drawbacks

Novel multifunctional cyclodextrin-based nanocarriers for drug encapsulation and delivery as a strategy to overcome current therapeutic drawbacks

Objective

There is a high demand for the development of new drug delivery strategies to combat major diseases in our society, particularly cancer. Current treatments are based on high efficacy drugs, however their non-selective uptake by both normal and tumor cells as well as the development of multidrug resistance (MDR), constitute major hurdles. Resistance is also associated with the use of nucleoside analogues as anticancer drugs in vivo. Photodynamic therapy (PDT), aims at selectively killing neoplastic lesions by the combined action of a photosensitizer and visible light. Passive targeting, involving enhanced permeability and retention effect, allows the accumulation of drugs on tumor sites, and concomitant active targeting with suitable functionalities, constitute properties currently associated with polymeric delivery systems. Cyclodextrins (CDs) are biocompatible and biodegradable oligosaccharide nanocages, known to improve the solubility, stability and bioavailability of drugs. Scattered literature reports incidents that CDs may constitute potential means to overcome certain forms of MDR, or to effectively deliver photosensitizing anticancer drugs preserving their photodynamic properties. This network, highly specialized in CD chemistry, photochemistry, in vitro drug evaluation and in vivo applications, proposes to synthesize diverse families of new CD derivatives to build a platform of CD-based drug delivery nanosystems with a variety of architectures. These new generation nanocarriers, encompassing many cavities in a nm-sized vehicle, will possess high drug loading capacity, improved permeability and retention effect, enhanced targeting and complete biocompatibility. Their mode of action will be assessed in vitro and in vivo. These goals will be achieved via a strong training program of ESRs and ERs in a highly collaborating, multidisciplinary and application oriented program, with full participation of an SME partner, a leader in CD applications.

Coordinator

"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""

Address

End Of Patriarchou Grigoriou E And 27 Neapoleos Street
15341 Agia Paraskevi

Greece

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 411 432

Administrative Contact

Styliani Martaki (Ms.)

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSIDAD DE CASTILLA - LA MANCHA

Spain

EU Contribution

€ 324 040

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 348 297

HASKOLI ISLANDS

Iceland

EU Contribution

€ 249 269

UNIVERSITA DEGLI STUDI DI CATANIA

Italy

EU Contribution

€ 299 649

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 211 603

GOETEBORGS UNIVERSITET

Sweden

EU Contribution

€ 218 583

UNIVERSIDAD DE ALMERIA

Spain

EU Contribution

€ 195 917

CYCLOLAB CIKLODEXTRIN KUTATO-FEJLES

Hungary

EU Contribution

€ 156 757

Project information

Grant agreement ID: 237962

Status

Closed project

  • Start date

    1 October 2009

  • End date

    30 September 2013

Funded under:

FP7-PEOPLE

  • Overall budget:

    € 2 415 547

  • EU contribution

    € 2 415 547

Coordinated by:

"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""

Greece